Induction With Basiliximab in Renal Transplantation

Transplantation Proceedings

Volumn 42, Issue 2, 2010, Pages 467-470

  Ferrer, F ^a   Machado, S ^a   Alves, R ^a   Macario F ^a   Bastos, C ^a   Roseiro, A ^a   Mota, A ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY TITER; ARTICLE; CADAVER; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIALYSIS; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; CREATININE; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77949427870     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.01.039     Document Type: Article

References (14)

1. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 38 suppl 6 (2001) S44
2. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378
3. Salis P., Caccamo C., Verzaro R., et al. The role of basiliximab in the evolving renal transplantation immunosuppression protocol. Biologies: Targets and Therapy 2 (2008) 175
4. Kahan B.D., Rajagopalan P.R., and Hall M. Redeuction of the occurrence of acute celular rejection among renal transplants treated with basiliximab. United States Simulect Study Group. Transplantation 67 (1999) 276
5. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin 2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75 (2003) 37
6. Ponticelli C., Yussim A., Cambi V., et al. A randomized double blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261
7. Adu D., Cockwell P., Ives N.J., et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials. BMJ 326 (2003) 789
8. Tan J., Yang S., and Wu W. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients. Transplant Proc 37 (2005) 903
9. Koch M., Becker T., Lueck R., et al. Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years?. Biologics: Targets & Therapy 3 (2009) 51
10. Heifets M., Saeed M.I., Parikh M.H., et al. Induction immunosuppression in kidney transplant recipients older that 60 years of age: safety and efficacy of ATGAM®, OKT3® and Simulect®. Drugs Aging 21 (2004) 747
11. Webster A.C., Playford E.G., Higgins G., et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77 (2004) 166
12. Sola R., Alarcon A., Jimenez, et al. The influence of delayed graft function. Nephrol Dial Transplant 19 suppl 3 (2004) iii32
13. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 19 (2005) 705
14. Emparan C., Laukötter M., Wolters H., et al. Calcineurin-free protocols with basiliximab induction allow patients included in "old-to-old" programs to achieve standard kidney transplant function. Transplant Proc 35 (2003) 1326